Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.

Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts ...

The company has raised its payouts for 14 consecutive years, and its nearly 89% growth over the last 10 years provides a ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that scientific and commercial team leaders will host a virtual investor event where they will give an overview ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Two new vaccine advisers tapped by Health and Human Services Secretary Robert F. Kennedy Jr. have served as paid expert ...

Merck launches AI-powered search, offering patients fast, trusted answers from its widely used medical manuals and resources.

The First Lady, Lordina Mahama, has commended Merck Foundation for strengthening the healthcare system in Ghana and Africa ...